Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Shandong Luoxin gains exclusive rights to Yuhan's preclinical cancer project

Executive Summary

Shandong Luoxin Pharmaceutical Group Co. Ltd. (also referred to as Shandong Elohim Pharmaceutical) licensed exclusive rights to develop, manufacture, and sell Yuhan Corp.'s preclinical non-small cell lung cancer candidate YH25448 in China, Hong Kong, and Macau.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register